

1646

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: 4/17/03 Signature: Anna P. Lucey
(Anna P. Lucey)

Docket No.: JHUC-P01-017
(PATENT)

#14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 23 2003

In re Patent Application of:
Beachy et al.

Application No.: 09/943641

Group Art Unit: 1646

TECH CENTER 1600/2900

Filed: August 30, 2001

Examiner: Basi, Nirmal Singh

For: IDENTIFICATION OF ACTIVATED
RECEPTORS AND ION CHANNELS

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

A copy of each reference on PTO/SB/08 is attached.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.




In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents should one or more of the documents be applied against the claims of the present application.


The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. JHUC-P01-017.

Dated:

Respectfully submitted,

By  _____
Yu Lu

Registration No.: 50,306
ROPES & GRAY
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/943641
				Filing Date	August 30, 2001
				First Named Inventor	Philip A. Beachy
				Art Unit	1646
				Examiner Name	Basi, Nirmal Singh
Sheet	1	of	1	Attorney Docket Number	JHUC-P01-017

RECEIVED

APR 23 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	AA	WO 00/21987	04/20/2000	Arena Pharmaceuticals, Inc.		
	AB	WO 00/22131	04/20/2000	Behan et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AC	Han, M. et al. Constitutive Activation of Opsin by Mutation of Methionine 257 on Transmembrane Helix 6. Biochemistry 37, 8253-8261 (1998).		
	AD	Lu, D. et al. A Ligand-Mimetic Model for Constitutive Activation of the Melanocortin-1 Receptor. Mol. Endocrinol. 12, 592-604 (1998).		
	AE	McWhinney, C. et al. Constitutively Active Mutants of the alpha1a- and the alpha1b-Adrenergic Receptor Subtypes Reveal Coupling to Different Signaling Pathways and Physiological Responses in Rat Cardiac Myocytes. J. Biol. Chem. 275, 2087-2097 (21 Jan. 2000).		
	AF	Pauwels, P.J. and Wurch, T. Review: Amino Acid Domains Involved in Constitutive Activation of G-Protein-Coupled Receptors. Mol. Neurobiol. 17, 109-135 (1998).		
	AG	Somers, C.M. et al. A Limited Spectrum of Mutations Causes Constitutive Activation of the Yeast alpha-Factor Receptor. Biochemistry 39, 6898-6909 (2000).		
	AH	Spalding, T.A. et al. Constitutive Activation of the m5 Muscarinic Receptor by a Series of Mutations at the Extracellular End of Transmembrane 6. Biochemistry 36, 10109-10116 (1997).		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--